<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01596270</url>
  </required_header>
  <id_info>
    <org_study_id>TED12471</org_study_id>
    <secondary_id>U1111-1123-1488</secondary_id>
    <nct_id>NCT01596270</nct_id>
  </id_info>
  <brief_title>A Study of the Safety and Pharmacokinetics of SAR245409 Tablets in Patients With Solid Tumors or Lymphoma</brief_title>
  <official_title>A Phase 1 Dose-escalation Study of the Safety and Pharmacokinetics of a Tablet Formulation of SAR245409 Administered Daily to Patients With Solid Tumors or Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      - To evaluate the safety and tolerability of SAR245409 tablets administered once or twice a&#xD;
      day in patients with solid tumors or lymphoma.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        -  To evaluate blood levels of SAR245409 after administration of SAR245409 tablets once or&#xD;
           twice a day in patients with solid tumors or lymphoma.&#xD;
&#xD;
        -  To evaluate the effect of food on blood levels of SAR245409 after administration of&#xD;
           SAR245409 tablets in patients with solid tumors or lymphoma.&#xD;
&#xD;
        -  To evaluate the effect of SAR245409 on the body after administration of SAR245409&#xD;
           tablets once or twice a day in patients with solid tumors or lymphoma.&#xD;
&#xD;
        -  To obtain information on how SAR245409 administered once or twice a day to patients with&#xD;
           solid tumors or lymphoma affect disease symptoms and study treatment side effects as&#xD;
           reported by the patients on a questionnaire.&#xD;
&#xD;
        -  To explore the antitumor activity of SAR245409 tablets administered once or twice a day&#xD;
           to patients with solid tumors or lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The total study duration per patient will be 58 to 128 days and will include a screening&#xD;
      period (1 to 28 days), a food interaction investigation period (when applicable; 4 to 11&#xD;
      days), two 28-day treatment cycles (56 days), an end-of-treatment visit (within 7 days after&#xD;
      the last SAR245409 administration) and a follow-up visit (within 30 Â± 3 days after the last&#xD;
      SAR245409 administration).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Limiting Toxicities</measure>
    <time_frame>Up to Day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with treatment-emergent adverse events</measure>
    <time_frame>From first dose of SAR245409 until 30 days after the last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum SAR245409 plasma concentration</measure>
    <time_frame>Cycle 1 Days 1, 2, 8, 15, and 28, and Cycle 2 Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the SAR245409 plasma concentration versus time curve</measure>
    <time_frame>Cycle 1 Days 1, 2, 8, 15, and 28, and Cycle 2 Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of maximum SAR245409 plasma concentration between fed and fasted dosing</measure>
    <time_frame>Days 1, 2, 3, and 4 of the food interaction period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of area under the SAR245409 plasma concentration versus time curve between fed and fasted dosing</measure>
    <time_frame>Days 1, 2, 3, and 4 of the food interaction period</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Neoplasm Malignant</condition>
  <arm_group>
    <arm_group_label>Once daily dosing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>escalating doses, once daily dosing every day, no eating for 2 hours prior and 1 hour after dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Twice daily dosing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>escalating doses, twice daily dosing every day, no eating for 2 hours prior and 1 hour after dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SAR245409</intervention_name>
    <description>Pharmaceutical form: tablet Route of administration: oral</description>
    <arm_group_label>Once daily dosing</arm_group_label>
    <arm_group_label>Twice daily dosing</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :&#xD;
&#xD;
          -  Solid tumor that is metastatic or unresectable, or relapsed or refractory lymphoma&#xD;
             (including chronic lymphocytic leukemia/small lymphocytic lymphoma), for which&#xD;
             standard therapies are no longer effective or there are no therapies known to prolong&#xD;
             survival.&#xD;
&#xD;
          -  Male or female patient &gt; or = 18 years old.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group Performance Status &lt; or = 1.&#xD;
&#xD;
          -  Adequate white blood cells, platelets and haemoglobin.&#xD;
&#xD;
          -  Adequate liver and kidney functions.&#xD;
&#xD;
          -  Fasting plasma glucose &lt; 160 mg/dL.&#xD;
&#xD;
          -  No other malignancy.&#xD;
&#xD;
          -  Women of childbearing potential using adequate contraception.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  History of partial or full gastrectomy.&#xD;
&#xD;
          -  Lymphoma involving the gastrointestinal tract.&#xD;
&#xD;
          -  Uncontrolled brain metastases or a primary brain tumor.&#xD;
&#xD;
          -  Prior treatment with cytotoxic chemotherapy (including investigational agents) or&#xD;
             biologic agents (antibodies, immune modulators, and cytokines) within 4 weeks, or&#xD;
             nitrosoureas or mitomycin C within 6 weeks, before the first dose of study treatment.&#xD;
&#xD;
          -  Prior treatment with a small-molecule kinase inhibitor (including investigational&#xD;
             agents) within 2 weeks, or 5 half lives of the drug or active metabolites, whichever&#xD;
             is longer, before the first dose of study treatment.&#xD;
&#xD;
          -  Any other investigational therapy within 4 weeks before the first dose of study&#xD;
             treatment.&#xD;
&#xD;
          -  Prior anticancer hormonal therapy within 1 week before the first dose of study&#xD;
             treatment.&#xD;
&#xD;
          -  Prior radiation therapy within 2 weeks before the first dose of study treatment.&#xD;
&#xD;
          -  Intolerance of prior treatment with a PI3K inhibitor.&#xD;
&#xD;
          -  Hereditary or acquired immunodeficiency syndrome or HIV (human immunodeficiency virus)&#xD;
             infection.&#xD;
&#xD;
          -  Lymphoma patients with positive serologies for Hepatitis B surface antigen (HBsAg) or&#xD;
             anti-Hepatitis C virus (anti-HCV) antibodies.&#xD;
&#xD;
          -  Positive serologies for Hepatitis B surface antigen (HBsAg) or anti-Hepatitis C virus&#xD;
             (anti-HCV) antibodies.&#xD;
&#xD;
          -  Patient is pregnant or breastfeeding.&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 840001</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840002</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840003</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <study_first_submitted>May 9, 2012</study_first_submitted>
  <study_first_submitted_qc>May 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2012</study_first_posted>
  <last_update_submitted>October 27, 2020</last_update_submitted>
  <last_update_submitted_qc>October 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

